Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Genital Neoplasms, Male × Androgen Antagonists × 1 year × Clear all

Sponsor

Conditions

Prostatic Neoplasms 50 Neoplasm Metastasis 4 Adenocarcinoma 3 Prostate Cancer Metastatic 2 Prostate CA 2 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 Triple Negative Breast Neoplasms 1 Stage IV Prostate Adenocarcinoma AJCC v7 1 Salivary Gland Neoplasms 1 Recurrence 1 Prostatic Diseases 1 Prostate Adenocarcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 PSA Level Greater Than 0.03 1 Oligometastatic Prostate Cancer 1 Neoplasms 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1 Metastatic Hormone-Sensitive Prostate Cance 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Lymphatic Metastasis 1 Intraprostatic Prostate Cancer 1 Hormone Sensitive Prostate Cancer 1 Erectile Dysfunction 1 Breast Neoplasms 1 Adenocarcinoma of the Prostate 1

Interventions

olaparib 1 gallium 68 PSMA-11 1 Pluvicto 1 Abiraterone Acetate 1 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1 (225)Ac-PSMA-617 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡